Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
In a study, median survival time was significantly shorter among patients managed nonsurgically rather than surgically for localized upper tract urothelial carcinoma.
Elevated C-reactive protein levels prior to nephrectomy for renal cell carcinoma is associated with an increased risk of renal impairment, a study found.
In a study, left-sided renal cell carcinoma (RCC) was associated with a 15% to 20% increased risk of dying from the malignancy compared with right-sided RCC.
Adjuvant chemotherapy given to patients following underwent radical surgery for locally advanced upper tract urothelial carcinoma was associated with a significantly decreased risk of tumor recurrence.
FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.
The approval was supported by data from a phase 2 multicenter, open-label, single-arm trial (N=87) of patients with locally advanced or metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations that had progressed following treatment with chemotherapy.
In a large population-based study in Sweden, statin users had significant 31% increased odds of nonmuscle-invasive bladder cancer compared with nonusers.
A high monocyte-to-lymphocyte ratio and a high platelet-to-lymphocyte ratio were predictive of poor OS in patients with advanced gallbladder cancer treated with chemotherapy.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
